Advertisement

Comparative assessment of hypothalamic-pituitary-adrenal axis suppression secondary to intrabursal injection of different glucocorticoids: a pilot study

  • F. GuaraldiEmail author
  • D. Gori
  • P. Calderoni
  • E. Castiello
  • L. Pratelli
  • M. Leporati
  • E. Arvat
  • M. Battaglia
Original Article
  • 11 Downloads

Abstract

Background

Hypothalamic-pituitary-adrenal axis (HPAA) suppression is the most common and dangerous, although often unrecognized and untreated, side effect of glucocorticoid administration. The risk and duration depend both on patient and treatment characteristics. High-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS) currently represents the gold standard method to evaluate the metabolism of endogenous and exogenous steroids.

Objective

To assess prevalence, severity, and duration of HPAA suppression subsequent to the injection of two steroids with equivalent potency but different pharmacokinetics.

Subjects and methods

Single-blind randomized case–control pilot study. Forty patients (22 F; age 48.7 ± 7.2 years) with shoulder calcific tendinopathy received an intrabursal injection of 40 mg of 6α-methylprednisolone acetate (MA) or triamcinolone acetonide (TA). Just before (T0) and after 1 (T1), 7 (T2), 15 (T3), 30 (T4) and 45 (T5) days, we assessed morning blood cortisol and ACTH by RIA, and 24-h urinary levels of MA, TA and free cortisol by HPLC–MS/MS.

Results

HPAA function was normal at baseline. At T1, all patients presented HPAA suppression reaching the lowest cortisol, ACTH and UFC levels, that were similar between groups. At T2, mean cortisol remained lower than at baseline (p < 0.0001) in the TA group. In both groups, mean cortisol and ACTH levels progressively normalized, suggesting HPA recovery, except for three patients in the MA and two in the TA group. UFC levels remained lower than normal (p < 0.0001) up to T5, despite the disappearance of exogenous GCs. No patient developed manifestations of hypocortisolism.

Conclusions

A single 40-mg intrabursal injection of MA or TA is sufficient to suppresses HPAA up to 45 days. Although typically asymptomatic, patients should be instructed to recognize and report symptoms suggestive for hypocortisolism, to provide prompt diagnosis, and eventually, treatment, thus avoiding severe complications.

Keywords

Adrenal insufficiency Glucocorticoids Methylprednisolone acetate Triamcinolone acetonide Liquid chromatography-tandem mass spectrometry 

Notes

Funding

The study was supported by a IRCCS Rizzoli Orthopaedic Institute research grant to M.B.

Compliance with ethical standards

Financial disclosure

The Authors declare they have nothing to disclose.

Conflict of interest

The Authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Battaglia M, Guaraldi F, Gori D, Castiello E, Arvat E, Sudanese A (2017) Efficacy of triamcinolone acetate and methylprednisolone acetonide for intrabursal injection after ultrasound-guided percutaneous treatment in painful shoulder calcific tendonitis: a randomized controlled trial. Acta Radiol 58(8):964–970.  https://doi.org/10.1177/0284185116678275 CrossRefPubMedGoogle Scholar
  2. 2.
    Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100(6):2171–2180CrossRefPubMedGoogle Scholar
  3. 3.
    Crowley RK, Argese N, Tomlinson JW, Stewart PM (2014) Central hypoadrenalism. J Clin Endocrinol Metab 99(11):4027–4036.  https://doi.org/10.1210/jc.2014-2476 CrossRefPubMedGoogle Scholar
  4. 4.
    Grossman AB (2010) Clinical review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 95(11):4855–4863.  https://doi.org/10.1210/jc.2010-0982 CrossRefPubMedGoogle Scholar
  5. 5.
    Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(2):364–389.  https://doi.org/10.1210/jc.2015-1710 CrossRefPubMedGoogle Scholar
  6. 6.
    Guaraldi F, Karamouzis I, Berardelli R, D'Angelo V, Rampino A, Zichi C, Ghigo E, Giordano R (2016) Secondary adrenal insufficiency: Where is it hidden and what does it look like? Front Horm Res. 46:159–170.  https://doi.org/10.1159/000443915 CrossRefPubMedGoogle Scholar
  7. 7.
    Guerrero Pérez F, Marengo AP, Villabona Artero C (2017) The unresolved riddle of glucocorticoid withdrawal. J Endocrinol Invest. 40(11):1175–1181.  https://doi.org/10.1007/s40618-017-0691-1 CrossRefPubMedGoogle Scholar
  8. 8.
    Habib GS (2009) Systemic effects of intra-articular corticosteroids. Clin Rheumatol 28(7):749–756CrossRefPubMedGoogle Scholar
  9. 9.
    Habib G, Jabbour A, Artul S, Hakim G (2014) Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic-pituitary-adrenal axis: a randomized controlled study. Clin Rheumatol 33(1):99–103CrossRefPubMedGoogle Scholar
  10. 10.
    Hopkins RL, Leinung MC. Exogenous cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 2005;34(2):371-84,  https://doi.org/10.1016/j.ecl.2005.01.013 (ix)CrossRefPubMedGoogle Scholar
  11. 11.
    Huang W, Kalhorn TF, Baillie M, Shen DD, Thummel KE (2007) Determination of free and total cortisol in plasma and urine by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 29(2):215–224.  https://doi.org/10.1097/FTD.0b013e31803d14c0 CrossRefPubMedGoogle Scholar
  12. 12.
    Johnston PC, Lansang MC, Chatterjee S, Kennedy L (2015) Intra-articular glucocorticoid injections and their effect on hypothalamic-pituitary-adrenal (HPA)-axis function. Endocrine 48(2):410–416.  https://doi.org/10.1007/s12020-014-0409-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Kulle AE, Welzel M, Holterhus PM, Riepe FG (2011) Principles and clinical applications of liquid chromatography—tandem mass spectrometry for the determination of adrenal and gonadal steroid hormones. J Endocrinol Invest. 34(9):702–708.  https://doi.org/10.3275/7843 PubMedGoogle Scholar
  14. 14.
    Lansang MC, Farmer T, Kennedy L (2009) Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr Pract 15(3):225–228.  https://doi.org/10.4158/ep.15.3.225 CrossRefPubMedGoogle Scholar
  15. 15.
    Lazarevic MB, Skosey JL, Djordjevic-Denic G, Swedler WJ, Zgardic I, Myones BL (1995) Reduction of cortisol levels after single intra-articular and intramuscular steroid injection. Am J Med 99(4):370–373CrossRefPubMedGoogle Scholar
  16. 16.
    Mader R, Lavi L, Luboshitzky R (2005) Evaluation of the pituitary- adrenal axis function following single intra-articular injection of methylprednisolone. Arth Rheum 52(3):924–928CrossRefGoogle Scholar
  17. 17.
    Nieman LK (2003) Dynamic evaluation of adrenal hypofunction. J Endocrinol Invest 26:74–82PubMedGoogle Scholar
  18. 18.
    Pekarek B, Osher L, Buck S, Bowen M (2011) Intra-articular corticosteroid injections: a critical literature review with up-to-date findings. Foot (Edinb) 21(2):66–70.  https://doi.org/10.1016/j.foot.2010.12.001 CrossRefGoogle Scholar
  19. 19.
    Rozental TD, Sculo TP (2000) Intra-articular corticosteroids: an updated overview. Am J Orthop 29(1):18–23PubMedGoogle Scholar
  20. 20.
    Turpeinen U, Hämäläinen E. Determination of cortisol in serum, saliva and urine. Best Pract Res Clin Endocrinol Metab 2013;27(6):795-801.  https://doi.org/10.1016/j.beem.2013.10.008 CrossRefPubMedGoogle Scholar
  21. 21.
    Weitoft T, Ronnblom L (2006) Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. Ann Rheum Dis 65(7):955–957CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  • F. Guaraldi
    • 1
    Email author
  • D. Gori
    • 2
  • P. Calderoni
    • 3
  • E. Castiello
    • 3
  • L. Pratelli
    • 4
  • M. Leporati
    • 5
  • E. Arvat
    • 6
  • M. Battaglia
    • 7
  1. 1.Pituitary Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna—Department of Biomedical and Neuromotor SciencesUniversity of BolognaBolognaItaly
  2. 2.Department of Biomedical and Neuromotor SciencesUniversity of BolognaBolognaItaly
  3. 3.Department of Prosthetic Surgery and Revision of Hip and Knee ImplantsIRCCS Rizzoli Orthopaedic InstituteBolognaItaly
  4. 4.Clinical Pathology ServiceIRCCS Rizzoli Orthopaedic InstituteBolognaItaly
  5. 5.Centro Regionale Antidoping “A. Bertinaria”TurinItaly
  6. 6.Division of Oncological Endocrinology, Department of Medical SciencesUniversity of TurinTurinItaly
  7. 7.Division of Diagnostic and Interventional RadiologyIRCCS Rizzoli Orthopaedic InstituteBolognaItaly

Personalised recommendations